Illumina成立“AI相关新部门”

Core Insights - Illumina has established a new business unit called BioInsight, focusing on large project contracting, data sharing platforms, and the development of multi-omics AI tools to enhance sequencing business integration and intelligence upgrades [1][2] Group 1: New Business Unit - The new business unit BioInsight will be divided into three main areas: national large project contracting, building a data sharing platform, and developing AI tools for strategic partners and multi-omics analysis [1] - Rami Mehio, previously the global software and IT head at Edico Genome, has been appointed as the General Manager of BioInsight [2] Group 2: Market Challenges - Illumina faces significant challenges globally, including technological competition from emerging sequencing companies, a highly competitive market environment, poor financial performance, and management instability [2] - In the Chinese market, Illumina's challenges are particularly pronounced, having been placed on the "unreliable entity list" in February 2025, which has closed export channels for core equipment to China [2] - In 2024, Illumina's revenue in the Greater China region declined by 16% year-on-year, with market share dropping from 59% in 2020 to approximately 12.36% in the first three quarters of 2024, leading many commercial users to switch to domestic sequencing instruments [2]